Roche's skin cancer drug Erivedge was approved by the U.S. FDA to treat patients with a common form of skin cancer, basal cell carcinoma (BCC). Erivedge, also named as vismodegib,  is the first drug available to treat basal cell cancer that has ...

Amgen Inc agreed to buy drug developer Micromet Inc. in a $1.16 billion deal aimed to bolster its oncology drug development pipeline. The world's largest biotechnology company Amgen said on Thursday it would pay $11 per share in cash for Micromet ...

Celgene Corp is going to acquire the private biotechnology company Avila Therapeutics for as much as $925 million in cash and potential milestone payments. The Summit, NJ-based Celgene will pay $350 million in cash for the Bedford, MA-based Avila. In addition, ...

Bayer is getting closer to the new drug application for its investigational cancer drug regorafenib as the company reports the impressive data from the late-stage study of regorafenib in advanced colorectal cancer patients. According to a study presented on Jan. 21 at the American Society of ...

The US FDA has issued a complete response letter refusing approval of AstraZeneca and Bristol-Myers Squibb diabetes drug candidate dapagliflozin. The U.S. agency requests additional clinical data to "allow a better assessment of the benefit-risk profile for dapagliflozin", said the two companies ...

Takeda Pharmaceutical has unveiled plans of business restructuring which will see 2,800 job cuts by the year ending March 2016. Japan's largest pharma company said the company will cut about 9 percent of its 30,000 workforce through job reductions in Europe and U.S.  over the next four ...

Pfizer and its partner Medivation have pulled the plug on their collaboration program of potential Alzheimer’s disease treatment Dimebon, as the drug candidate failed in another late- stage trial. The two companies said Tuesday that dimebon failed to achieve statistically significant results for either improving cognitive ability or ...

Novartis plans to cut nearly 2,000  jobs in the U.S. as the company restructures its U.S. operations, and prepares for the challenging of patent loss of its top-selling blood pressure drug Diovan. The Basel-based Swiss pharma company says the job cuts will affect 1,630 ...

Boehringer Ingelheim’s anticoagulant drug Pradaxa (Dabigatran) increased patients' risk of heart attack or severe chest pain, according to a review of studies published recently. The new meta-analysis study shows that Pradaxa, the first drug to gain approval as part of a ...

Bristol-Myers Squibb is going to acquire Inhibitex Inc, a biopharma developer dedicated to infectious diseases. The $2.5 billion cash deal will boost BMS development  pipeline in hepatitis C treatments. The companies announced in a statement that BMS will pay $26 a share through a two-step merger, beginning with ...